Market Overview

UPDATE: Canaccord Genuity Upgrades Mylan to Buy

Related MYL
Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe
Watch These 7 Huge Put Purchases In Wednesday Trade

Canaccord Genuity raised its rating on Mylan (NASDAQ: MYL) from Hold to Buy and increased its price target from $25 to $30.

Canaccord Genuity commented, "Relative to follow-through, two things have changed: (1) upside from the quarter brings carry-through and an upward bias to guidance; (2) the message around potential for a sizable accretive deal will keep focus in the upside case and point many to the outperformance we saw by WPI off its Actavis purchase. Collectively, both should tactically push the stock higher into the early Feb. guidance update (with 4Q)."

Mylan closed at $25.00 on Thursday.

Latest Ratings for MYL

Jun 2017Cantor FitzgeraldInitiates Coverage OnNeutral
May 2017BarclaysUpgradesEqual-WeightOverweight
Jan 2017CitigroupDowngradesBuyNeutral

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (MYL)

View Comments and Join the Discussion!